新藥物動向：肌肉骨骼疾病藥物 是由出版商Espicom Business Intelligence在2006年05月所出版的。
這份英文市場調查報告書包含44 PAGES 價格從美金1320起跳。
中樞神經疾病是全球第六大的治療領域，2005 年全球市場規模為 228 億美元。歐美市場有強烈成長趨勢，銷售額美國佔 54％，歐洲雖佔 23％，但未來有減速趨勢。
提供醫療儀器、藥品相關情報，獲得全球高度評價的英國市調公司 Espicom Business Intelligence，調查分析了肌肉骨骼疾病的新藥物後，出版了一本綜合報告書"New Drug Futures: Musculoskeletal"。
報告書內容包括：市場動向、銷售變化、患者人口、目前治療概要、各企業概要、藥物詳細資訊等等，內容綱要摘記如下：
目前市場規模
抗風濕藥物銷售
抗骨質疏鬆症藥物銷售
患者人口
目前治療
- 關節風濕治療
- 骨質疏鬆症治療
- 關節風濕藥物銷售促進要素
- 關節風濕藥物銷售阻礙要素
- 骨質疏鬆症藥物銷售促進要素
- 骨質疏鬆症藥物銷售阻礙要素
未來治療
市場動向：勝方與敗方
2010 年前市場主要藥物
評估基準
2010 年前主要藥物
- Actemra (Roche/中外製藥株式會社)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Bazedoxifene (Wyeth)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Cimzia (UCB/Celltech)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- CNTO 148 (Johnson & Johnson/Schering-Plough)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Denosumab (Amgen)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Entereg (GlaxoSmithKline/Adolor)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Febuxostat (TAP Pharmaceutical Products)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Orencia (Bristol-Myers Squibb)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
- Preos (NPS Pharmaceuticals)
- 新功能、效能
- 概念實證、臨床資料
- 管理與臨床專門性
- 市場競爭、市佔率獲取
- 治療層級中研發新藥物伴隨的風險
- 登錄與認可
- 銷售預測與假設
- 競爭公司分析
競爭公司分析：總結
競爭公司分析：企業
Abstract
This chapter of New Drug Futures evaluates, compares and contrasts the
prospects for the compounds that will revolutionise the pharmaceutical
industry over the next 5 years and beyond in the musculoskeletal sector. The
report includes unique sales forecasts by major product.
The full 400-page report, evaluates, compares and contrasts the prospects for
the compounds that will revolutionise the pharmaceutical industry over the
next 5 years and beyond. The report covers 8 key therapy areas
(alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS,
musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by
major product. Click here for more information. This chapter is available
separately.
The musculoskeletal market is the sixth largest therapeutic category by sales
and generated over US$228 billion (+0.8% YoY) in 2005. Sales grew strongly in
the US and Europe which accounted for 54% and 23% of sales however, sales have
slowed significantly, largely due to the withdrawal of a number of COX-2
inhibitors during 2004 and early 2005.
Two of the largest segments of the musculoskeletal market are rheumatoid
arthritis (anti-rheumatics) and osteoporosis (bone calcium regulators). The
remaining sales are derived from the treatment of a mixture of aetiologies
such as anti-inflammatory conditions and muscle relaxants.
Table of Contents
CURRENT MARKET SIZE
ANTI-RHEUMATIC DRUG SALES
ANTI-OSTEOPOROSIS DRUG SALES
ADDRESSABLE PATIENT POPULATION
- RHEUMATOID ARTHRITIS
- OSTEOPOROSIS
CURRENT TREATMENTS
- RHEUMATOID ARTHRITIS TREATMENTS
- OSTEOPOROSIS TREATMENTS
- RHEUMATOID ARTHRITIS SALES DRIVERS
- OSTEOPOROSIS SALES DRIVERS
- RHEUMATOID ARTHRITIS SALES BREAKERS
- OSTEOPOROSIS SALES BREAKERS
FUTURE TREATMENTS
MARKET DYNAMICS - WINNERS & LOSERS
KEY DRUGS LAUNCHES BY 2010
KEY EVALUATION CRITERIA
KEY MUSCULOSKELETAL DRUG LAUNCHES BY 2010
- Actemra (Roche/Chugai)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Bazedoxifene (Wyeth)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Cimzia (UCB/Celltech)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- CNTO 148 (Johnson & Johnson/Schering-Plough)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Denosumab (Amgen)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Entereg (GlaxoSmithKline/Adolor)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Febuxostat (TAP Pharmaceutical Products)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Orencia (Bristol-Myers Squibb)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Preos (NPS Pharmaceuticals)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
COMPETITOR RATIO ANALYSIS SUMMARY
COMPETITOR RATIO ANALYSIS - COMPANIES
